Real World Adoption of FDA-approved Peanut Oral Immunotherapy with Palforzia

Mustafa, S Shahzad; Patrawala, Sara

doi:10.1016/j.jaci.2020.12.401

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first paper to assess real-world adoption of peanut immunotherapy with Palforzia found that of 237 peanut-allergic individuals, 22 (9.3%) chose to pursue peanut immunotherapy with Palforzia, whereas 215 (90.7%) declined therapy. 9 The two most common reasons to decline therapy were 'concern over adverse effects', and 'concern over the degree of commitment', cited by 35.4% and 28.5% of responding families, respectively. 9 Significantly, children age 8-12 years and caregivers with low quality of life as reported by their FAQL-CF were more likely to pursue therapy with Palforzia.…”

Section: Palforzia For Peanut Allergy: Panacea or Predicamentmentioning

confidence: 99%

“…9 Significantly, children age 8-12 years and caregivers with low quality of life as reported by their FAQL-CF were more likely to pursue therapy with Palforzia. 9 So potentially what improvements are being presented as occurring after successful peanut immunotherapy reflect a selection bias of those with significantly reduced quality of life at baseline. The question, therefore, is whether for the majority with higher baseline quality-of-life scores, is consideration of peanut immunotherapy even necessary?…”

Section: Palforzia For Peanut Allergy: Panacea or Predicamentmentioning

confidence: 99%

“…The first paper to assess real‐world adoption of peanut immunotherapy with Palforzia found that of 237 peanut‐allergic individuals, 22 (9.3%) chose to pursue peanut immunotherapy with Palforzia, whereas 215 (90.7%) declined therapy 9 …”

mentioning

confidence: 99%

“…The two most common reasons to decline therapy were ‘concern over adverse effects’, and ‘concern over the degree of commitment’, cited by 35.4% and 28.5% of responding families, respectively. 9 Significantly, children age 8–12 years and caregivers with low quality of life as reported by their FAQL‐CF were more likely to pursue therapy with Palforzia 9 . So potentially what improvements are being presented as occurring after successful peanut immunotherapy reflect a selection bias of those with significantly reduced quality of life at baseline.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Palforzia for peanut allergy: Panacea or predicament

Perkin

2022

Clin Experimental Allergy

View full text Add to dashboard Cite

Section: Palforzia For Peanut Allergy: Panacea or Predicamentmentioning

confidence: 99%

Section: Palforzia For Peanut Allergy: Panacea or Predicamentmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Palforzia for peanut allergy: Panacea or predicament

Perkin

2022

Clin Experimental Allergy

View full text Add to dashboard Cite

“…Palforzia is associated with a high rate of adverse effects and relapse after treatment cessation ( 20 ). Moreover, real-world acceptance of Palforzia is reported to be low ( 21 ). Therefore, the need to develop treatments, particularly for milk and peanut (PN) allergies, is urgent and challenging.…”

Section: Introductionmentioning

confidence: 99%

Sustained silencing peanut allergy by xanthopurpurin is associated with suppression of peripheral and bone marrow IgE-producing B cell

Yang,

Srivastava,

Chen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionPeanut allergy is an immunoglobulin E (IgE) mediated food allergy. Rubia cordifolia L. (R. cordifolia), a Chinese herbal medicine, protects against peanut-induced anaphylaxis by suppressing IgE production in vivo. This study aims to identify IgE-inhibitory compounds from the water extract of R. cordifolia and investigate the underlying mechanisms using in vitro and in vivo models.MethodsCompounds were isolated from R. cordifolia water extract and their bioactivity on IgE production was assessed using a human myeloma U266 cell line. The purified active compound, xanthopurpurin (XPP), was identified by LC-MS and NMR. Peanut-allergic C3H/HeJ mice were orally administered with or without XPP at 200µg or 400µg per mouse per day for 4 weeks. Serum peanut-specific IgE levels, symptom scores, body temperatures, and plasma histamine levels were measured at challenge. Cytokines in splenocyte cultures were determined by ELISA, and IgE + B cells were analyzed by flow cytometry. Acute and sub-chronic toxicity were evaluated. IL-4 promoter DNA methylation, RNA-Seq, and qPCR analysis were performed to determine the regulatory mechanisms of XPP.ResultsXPP significantly and dose-dependently suppressed the IgE production in U266 cells. XPP significantly reduced peanut-specific IgE (>80%, p <0.01), and plasma histamine levels and protected the mice against peanut-allergic reactions in both early and late treatment experiments (p < 0.05, n=9). XPP showed a strong protective effect even 5 weeks after discontinuing the treatment. XPP significantly reduced the IL-4 level without affecting IgG or IgA and IFN-γ production. Flow cytometry data showed that XPP reduced peripheral and bone marrow IgE + B cells compared to the untreated group. XPP increased IL-4 promoter methylation. RNA-Seq and RT-PCR experiments revealed that XPP regulated the gene expression of CCND1, DUSP4, SDC1, ETS1, PTPRC, and IL6R, which are related to plasma cell IgE production. All safety testing results were in the normal range.ConclusionsXPP successfully protected peanut-allergic mice against peanut anaphylaxis by suppressing IgE production. XPP suppresses murine IgE-producing B cell numbers and inhibits IgE production and associated genes in human plasma cells. XPP may be a potential therapy for IgE-mediated food allergy.

show abstract

Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia™) in peanut allergy: a profile of its use

Heo

2021

Drugs Ther Perspect

View full text Add to dashboard Cite

Real World Adoption of FDA-approved Peanut Oral Immunotherapy with Palforzia

Cited by 6 publications

References 0 publications

Palforzia for peanut allergy: Panacea or predicament

Palforzia for peanut allergy: Panacea or predicament

Sustained silencing peanut allergy by xanthopurpurin is associated with suppression of peripheral and bone marrow IgE-producing B cell

Peanut (Arachis hypogaea) allergen powder-dnfp (Palforzia™) in peanut allergy: a profile of its use

Contact Info

Product

Resources

About